ASSEMBLY BIOSCIENCES INC
ASMBNASDAQTrading Snapshot
- Day Range
- $23.14 – $23.88
- 52-Week Range
- $21.80 – $39.71
- Volume
- $2.13B
- Avg Volume
- $2.24B
- Shares Outstanding
- 19.8M
- Next Earnings
- Dec 2, 2026
Fundamentals Snapshot
- Annual Revenue
- $72M
- Last Q Revenue
- $13M
- P/E Ratio
- 42.7
- P/S Ratio
- 6.2x
- EPS (TTM)
- $-0.00
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +70.4%
Why Investors Own ASMB
- ✓High-growth profile — revenue up -8.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 28% gross margin and 14% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ASSEMBLY BIOSCIENCES INC
ASMB
StockOtter · stockotter.spaceAbout ASSEMBLY BIOSCIENCES INC
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Best Momentum Stocks to Buy for September 17th
MSGM, ASMB and MTG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 17th, 2026.
New Strong Buy Stocks for September 17th
MOV, MAX, MTG, ASMB and MSGM have been added to the Zacks Rank #1 (Strong Buy) List on September 17th, 2026.
Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today anno
Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks
COCO, CHEF, ASMB and CDNA stand out as four defensive picks amid volatility induced by rising oil prices and Middle East tensions.
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program
– Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor program for recurrent genital herpes –
Wall Street Analysts See a 35.71% Upside in Assembly Biosciences (ASMB): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 35.7% in Assembly Biosciences (ASMB). While the effectiveness of this highly sought-after metric is questionable, the positive tren